Abstract:
The remission rate of acute lymphoblastic leukemia (ALL) has gradually increased with the progression of immunotherapy and hematopoietic stem cell transplantation (HSCT). While the prognosis of relapsed or refractory ALL is still poor, blinatumomab, a bispecific CD19/CD3 T-cell engager, has been approved for treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) because of its efficacy. A number of clinical trials have demonstrated the efficacy of this agent in the frontline setting and in combination regimens such as cytotoxic chemotherapy and tyrosine kinase inhibitor. In this paper, the clinical trials and adverse events of the latest research progress on blinatumomab are reviewed.